Drug profile · INN
teriparatide
RITOSA
teriparatide (RITOSA) is a parathyroid hormone receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — teriparatide
- US status
- approved
- Class
- Systemic hormonal preparations (H05)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 7
- Data quality
- 0.89
Quick answer
teriparatide (RITOSA) is a parathyroid hormone receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Parathyroid hormone receptor agonist
Primary target: Parathyroid hormone/parathyroid hormone-related peptide receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is teriparatide?
teriparatide (RITOSA) is a parathyroid hormone receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for teriparatide?
RITOSA is a marketed brand name for teriparatide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of teriparatide?
teriparatide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.